REG - Sareum Holdings PLC - US Patent Grant for TYK2/JAK1 Anticancer Candidate

Sareum HoldingsAnnouncement

07/01/2021 07:02

For best results when printing this announcement, please click on link below:
http://newsfile.refinitiv.com/getnewsfile/v1/story?guid=urn:newsml:reuters.com:20210107:nRSG8256Ka&default-theme=true

RNS Number : 8256K  Sareum Holdings PLC  07 January 2021

SAREUM HOLDINGS PLC

("Sareum" or the "Company")

US Patent Formally Granted for Sareum's SDC-1802 TYK2/JAK1 Inhibitor

Cambridge, UK, 7 January 2021 - Sareum Holdings plc (AIM: SAR), the specialist
drug development company delivering targeted small molecule therapeutics to
improve the treatment of cancer and autoimmune diseases, is pleased to
announce that, further to its announcement of 8 October 2020, the United
States Patent and Trademark Office has now formally approved its patent
application (US Patent Application no. 16/351,620), in respect of an invention
associated with Sareum's proprietary SDC-1802 TYK2/JAK1 Kinase Inhibitor
Programme (the "SDC-1802 Programme"). This programme is in preclinical
development and targets cancer and cancer immunotherapy.

Following the grant of this patent (US 10,882,829), Sareum has patent
protection for the SDC-1802 molecule and pharmaceutical preparations thereof
in the US and across all major territories in Europe, Japan and China.

Sareum's CSO, Dr John Reader, commented:

"The granting of this patent in the US completes the protection of the
intellectual property for our proprietary SDC-1802 Programme across all major
markets. The Board believes that the patent will enhance the value of its
TYK2/JAK1 inhibitor programmes and the Company's negotiating position as it
continues to engage in discussions with potential licence partners."

 

For further information, please contact:

 Sareum Holdings plc

 Tim Mitchell, CEO                          01223 497 700

 Strand Hanson Limited (Nominated Adviser)

 James Dance / James Bellman                020 7409 3494

 Hybridan LLP (Nominated Broker)

 Claire Noyce / John Beresford-Peirse       020 3764 2341

 Citigate Dewe Rogerson (Financial PR)

 Mark Swallow/ David Dible                  020 7638 9571

 

About Sareum

Sareum is a specialist drug development company delivering targeted small
molecule therapeutics to improve the treatment of cancer and autoimmune
diseases. The Company aims to generate value through licensing its candidates
to international pharmaceutical and biotechnology companies at the preclinical
or early clinical trials stage.

Sareum is advancing internal programmes focused on distinct dual tyrosine
kinase 2 (TYK2) / Janus kinase 1 (JAK1) inhibitors through preclinical
development as therapies for autoimmune diseases, including the 'cytokine
storm' immune system overreaction to Covid-19 and other viral infections,
(SDC-1801) and cancer immunotherapy (SDC-1802).

The Company's preclinical FLT3+Aurora inhibitor programme targeting
haematological cancers is licensed to a China-based specialty pharma company.

Sareum also has an economic interest in SRA737, a clinical-stage oral,
selective Checkpoint kinase 1 (Chk1) inhibitor that targets cancer cell
replication and DNA damage repair mechanisms. Preliminary Phase 2 and
comprehensive preclinical data suggest SRA737 may have broad application in
combination with other oncology and immune-oncology drugs in genetically
defined patients.

SRA737 was discovered and initially developed by scientists at The Institute
of Cancer Research in collaboration with Sareum, and with funding from Sareum
and Cancer Research UK. SRA737 was licensed by CRT Pioneer Fund (CPF) to
Sierra Oncology Inc. Sierra continues to explore options that would enable the
development of SRA737 to advance.

Sareum Holdings plc is listed on the AIM market of the London Stock Exchange,
trading under the ticker SAR. For further information, please visit the
Company's website at www.sareum.com (http://www.sareum.com)

 

This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact
rns@lseg.com (mailto:rns@lseg.com)
 or visit
www.rns.com (http://www.rns.com/)
.

RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our
Privacy Policy (https://www.lseg.com/privacy-and-cookie-policy)
.   END  REAEASFKESKFEFA